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Abstract 
 
Cisplatin produces good responses in solid tumours including small cell lung cancer 
(SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to 
show activity against some cisplatin-resistant cancers but there is little known about 
oxaliplatin in SCLC and there are no reports of oxaliplatin resistant SCLC cell lines. 
Studies of drug resistance mainly focus on the cellular resistance mechanisms rather than 
how the cells develop resistance. This study examines the development of cisplatin and 
oxaliplatin resistance in H69 human SCLC cells in response to repeated treatment with 
clinically relevant doses of cisplatin or oxaliplatin for either 4 days or 2h. Treatments 
with 200ng/ml cisplatin or 400ng/ml oxaliplatin for 4 days produced sublines 
(H69CIS200 and H69OX400 respectively) that showed low level (approximately 2-fold) 
resistance after 8 treatments. Treatments with 1000ng/ml cisplatin or 2000ng/ml 
oxaliplatin for 2h also produced sublines, however these were not stably resistant 
suggesting shorter treatment pulses of drug may be more effective. Cells survived the 
first five treatments without any increase in resistance, by arresting their growth for a 
period and then regrowing. The period of growth arrest was reduced after the sixth 
treatment and the H69CIS200 and H69OX400 sublines showed a reduced growth arrest 
in response to cisplatin and oxaliplatin treatment suggesting that "regrowth resistance" 
initially protected against drug treatment and this was further upregulated and became 
part of the resistance phenotype of these sublines. Oxaliplatin dose escalation produced 
more surviving sublines than cisplatin dose escalation but neither set of sublines were 
associated with increased resistance as determined by 5-day cytotoxicity assays, also 
suggesting the involvement of regrowth resistance. The resistant sublines showed no 
change in platinum accumulation or glutathione levels even though the H69OX400 
subline was more sensitive to buthionine sulfoximine treatment. The H69CIS200 cells 
were cross-resistant to oxaliplatin demonstrating that oxaliplatin does not have activity 
against low level cisplatin resistance. Relative to the H69 cells, the H69CIS200 and 
H69OX400 sublines were more sensitive to paclitaxel and taxotere suggests the taxanes 
may be useful in the treatment of platinum resistant SCLC. These novel cellular models 
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of cisplatin and oxaliplatin resistant SCLC will be useful in developing strategies to treat 
platinum-resistant SCLC. 
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Introduction  
 
Cisplatin is a widely used chemotherapeutic drug in the treatment of solid tumours 
including small cell lung cancer [1]. The development of drug resistance is the primary 
reason for cisplatin’s failure to cure cancer. Over the last 30 years many other platinum 
drugs have been developed in an attempt to improve on cisplatin. One of these newer 
drugs is oxaliplatin which has activity against colon cancer in vitro [2] and is now used as 
a treatment for colon cancer in combination with 5-fluorouracil [3,4]. Oxaliplatin is also 
thought to be a better tolerated chemotherapeutic than cisplatin although cases of 
oxaliplatin toxicity have been reported [5,6].  
 
Oxaliplatin is widely regarded as useful for the treatment of cisplatin resistant cancer. 
Evidence for this comes from studies of cisplatin-resistant cell cultures and clinical 
studies. There is also the notion that because oxaliplatin has a different activity profile to 
cisplatin in the National Cancer Institute’s panel of 60 cell lines [7], oxaliplatin should 
complement cisplatin treatment and be effective against cisplatin resistance [2]. However, 
the evidence from cellular studies involve high levels of resistance (20- to 40- fold) to 
cisplatin [8,9]. While these highly resistant models are useful to understand the possible 
mechanisms of resistance, drug resistance in the clinical setting typically occurs at levels 
of 2-3 fold [10,11] and may therefore involve different mechanisms of resistance. 
 
The clinical evidence that oxaliplatin is active against cisplatin resistant cancers involves 
reports of oxaliplatin having greater activity against platinum pre-treated testicular cancer 
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when combined with other chemotherapeutics such as gemcitabine [12,13] or irrinotecan 
[14] rather than oxaliplatin as a single agent [15]. In these studies it is difficult to 
determine whether it is the oxaliplatin or the combination of drugs that produces a 
response in cisplatin pre-treated patients. This question is unlikely to be resolved by 
further clinical trails. The development of clinically relevant cellular models of cisplatin 
and oxaliplatin resistance would therefore help to resolve this issue. The way platinum 
resistance is defined in the clinic is also a complicating factor. Platinum pre-treated 
patients and clinical platinum resistance are not necessarily the same and different criteria 
are used in different clinical trails. When oxaliplatin was studied as a single agent in 
ovarian carcinoma where patients were divided into platinum resistant or platinum 
sensitive based on Markman’s criteria [16], there was a clear drop in response rate to 
oxaliplatin in the cisplatin resistant patients [17-19]. This suggests that oxaliplatin’s 
activity is reduced in cisplatin resistant cancer as this cohort failed to respond to 
oxaliplatin as a single agent. 
 
There are a variety of cisplatin-resistant SCLC sublines that have been established with 
various cisplatin treatment regimens and eleven examples are presented in Table 1. The 
majority of these studies focused on mechanisms of resistance and there was little 
information on how resistance developed or whether their sensitivity to oxaliplatin was 
altered. Seven of these sublines were produced by continuous cisplatin treatment for 
periods longer than a week and had cisplatin resistance from 5- to 25-fold. The other four 
sublines were repeatedly treated with cisplatin for 1h to 4 days and gave resistances of 2- 
to 16-fold. We chose to use pulsed rather than continuous drug exposure for our study of 
the development of resistance as this may result in low level and possibly more clinically 
relevant, resistance. Treatment doses were chosen in the range of IC10 – IC40 and are 
consistent with doses used in the clinical setting. Pharmacokinetic studies show that 
plasma platinum levels peak at a range of 1-10ug/ml in 2h with a rapid drop to the ng/ml 
range and then a slow decrease over the next 48 hours [20-21]. Our two time and dose 
strategies reflect these differing pharmacokinetic phases of the administration of platinum 
drugs; 2h treatments at 1000-8000ng/ml and 4 day treatments at 200-1600ng/ml. 
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There appear to be no reports of SCLC cells selected for oxaliplatin resistance. We report 
here the results of a comparative study of cisplatin and oxaliplatin and their ability to 
induce resistance in the human H69 SCLC cell line when administered repeatedly as 
either a 4 day or 2h pulse. The resistant cells produced were then maintained in drug-free 
media and their mechanisms of resistance and patterns of cross resistance between 
cisplatin, oxaliplatin and several other drugs were determined. 
 
Methods 
 
Cell Culture and Resistant Subline Development 
 
The human H69 small cell lung cancer cell line was obtained from the American Type 
Culture Collection. All cells and  sublines were maintained in drug free RPMI 
(Thermoelectron, Sydney, Australia) with 10% FCS (Thermoelectron) in a humidified 
atmosphere with 5% CO2 at 37°C. The H69 cells were treated as shown in Figure 1 with 
cisplatin for 4 days at doses of 200, 400 or 800 ng/ml; with cisplatin for 2h at doses of 
1000, 2000 or 4000ng/ml; with oxaliplatin for 4 days at doses of 400, 800 or 1600ng/ml; 
or with oxaliplatin for 2h at doses of 2000, 4000 or 8000ng/ml. Following treatment cells 
were transferred to drug-free culture conditions for recovery and when cultures had 
undergone approximately 5 doublings the treatment was repeated either at the same drug 
dose or at higher doses as indicated in Figure 1. Eight consecutive treatment cycles were 
performed on cultures over an 8 month period. All cultures were mycoplasma free.  
 
Cytotoxicity Assay 
 
To determine the level of  resistance, cells were plated into flat bottomed 96-well plates 
at a cell density of 6.0 x 10
4
 cells/well. Cells were treated in triplicate with 2-fold serial 
dilutions of drug in a final volume of 200 µl. Drug free controls were included in each 
assay. Plates were incubated for 5 days at 37°C in a humidified atmosphere with 5% CO2 
and cell viability was determined using the MTT assay [22]. 50 µl of MTT (2.5 mg/ml in 
PBS) was added to each well and the cells incubated for a further 2 hours. The plates 
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were centrifuged at 800g for 5 minutes, the culture medium aspirated and the formazan 
product dissolved in 100 µl DMSO.  Plates were mixed for 15 minutes and the 
absorbance measured at 570 nm. Cell viability was calculated as a percentage of control 
absorbance values and the fold resistance was calculated by dividing the IC50 of the 
resistant cells by that of the H69 cells. 
 
Glutathione Assay 
 
Total intracellular glutathione was determined using a modification of the colorimetric 
method of [23] as previously described [24]. 
 
Flow Cytometry Cell Cycle Analysis 
Cells (10
6
) were resuspended in 500 µl of Dubulco’s PBS containing 50 µg/ml propidium 
iodide and 0.02% nonodet P-40 on ice. The cells were then incubated on ice for 10-15 
minutes and analysed in a Becton Dickinson FACScan flow cytometer. Red fluorescence 
was monitored (FL2) using a 585/42 band pass filter, 10000 events were collected and 
the data was analysed using CellQuest software. 
 
Platinum Accumulation  
Cells (2.5 x 10
6
) were washed in 10 ml PBS, centrifuged and the supernatant carefully 
removed. The pellet of platinum treated cells was dried on a heating block, resuspended 
in 100 µl of nitric acid and incubated at 90°C for 3 hours. Samples were then resuspended 
in 200 µl of 0.1M HCl and analysed by Atomic Absorption using a Platinum Photron 
hollow cathode lamp in a Varian SpectrAA-400-Zeeman spectrophotometer using the 
operating conditions as specified by the manufacturer.  
 
Statistical Analysis 
 
The student’s t-test was used to determine significant differences. A P-value of less than 
0.05 was regarded to be significant. 
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RESULTS 
 
Development of platinum resistance 
 
The H69 cells were treated as shown in Figure 1 and as described in Methods. Of the 12 
different initial treatments, only the lowest drug concentrations produced surviving cells. 
These lowest drug concentration treatments all produced between 20 and 30% cell death 
and growth arrest. On drug treatment cells increased in size and did not aggregate in 
typical SCLC clumping morphology. Surviving cultures were then re-treated when their 
normal growth rate and clumping morphology had returned. Cultures were treated with 
the same drug and dose as well as with twice and four times that dose. All cultures again 
survived the lowest dose but none survived the higher doses except for those treated with 
4000ng/ml oxaliplatin for 2h. The results of the third treatment with the same and with 
escalated doses produced cultures that survived the same dose, none of the cultures 
treated with increased cisplatin doses survived while increased oxaliplatin produced two 
surviving cultures (Fig 1). Subsequent treatments with increased doses of cisplatin were 
performed out to treatment 4 which produced one culture that survived treatment with 
400ng/ml cisplatin for 4 days. Cultures therefore appeared to survive oxaliplatin dose 
escalation more easily than cisplatin dose escalation. However, those cultures surviving 
dose escalation were not more resistant than the cultures from which they were derived as 
determined by the standard 5 day cytotoxicity assay suggesting that this resistance may 
be associated with growth delay.  
 
Dose escalation of platinum drugs rarely occurs as part of SCLC treatment [25]. We 
therefore concentrated on characterising the development of resistance in the cultures 
repeatedly treated with the same lowest dose schedule. The initial treatments with 
cisplatin and oxaliplatin for 4 days produced a growth arrest and a time to doubling of 21 
days while the 2h treatments resulted in a 17 day recovery (Figure 2). A similar growth 
arrest occurred in all schedules for the first five treatments. For the sixth, seventh and 
eighth treatments, the recovery period was reduced to 6 days in all except the 2h cisplatin 
schedule. The cell sublines resulting from 8 treatments of the 4 day cisplatin schedule 
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were designated H69CIS200; the 2h cisplatin schedule, H69CIS1000; the 4 day 
oxaliplatin schedule, H69OX400 and the 2h oxaliplatin schedule, H69OX2000. The 
resistant cells were of the same size and morphology as the parental cells and grew at a 
similar growth rate in drug free media (data not shown). 
 
The level of resistance to cisplatin and oxaliplatin was monitored after each treatment at 
weekly intervals after recovery by performing a 5 day cytotoxicity assay. The results in 
Figure 3 show that for the 4 day cisplatin and oxaliplatin schedules, low level 
(approximately 2-fold), stable resistance developed following the eighth treatment. A 
similar level and pattern of stable cross-resistance to the non-selecting platinum drug was 
also evident. Although the 2h cisplatin and oxaliplatin schedules showed similar trends to 
those of the 4 day schedules (not shown), they did not produce stable resistance after the 
eighth treatment and therefore they were not included in further studies. Resistance to 
oxaliplatin was detected earlier than resistance to cisplatin in both sublines. A higher 
level of oxaliplatin resistance was also detected in comparison to cisplatin resistance in 
both resistant sublines. Resistance appeared to be greatest in the second week after 
recovery. However this resistance was transient as the level of resistance was usually 
lower in the third week. This variation was largest for the oxaliplatin treatments as 
compared to the cisplatin treatments and it was most evident at treatment 7. This 
increased variation may be related to the drop in doubling time at treatment 6 but may not 
be part of the progression to stable resistance as it did not re-occur at treatment 8. 
 
Changes associated with stable low level resistance 
The effect of an acute drug treatment on recovery time was determined by counting cells 
microscopically following treatment of the H69 cells and the H69CIS200 subline with 
1000ng/ml cisplatin for 2h and the H69 cells and the H69OX400 subline with 2000ng/ml 
oxaliplatin for 2h. Figure 4 shows that the doubling time after cisplatin treatment for the 
H69CIS200 subline was 10 days compared to 18 days for the H69 cells. The doubling 
time after oxaliplatin treatment was even shorter for the H69OX400 subline (5 days) 
compared to greater than 21 days for the H69 cells. These shorter doubling times were 
reflected in the time for the cell cycle to return to normal (Figure 5). When the H69 and 
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H69CIS200 cells were treated with 1000ng/ml cisplatin for 2h; the time for the recovery 
of the sub-G0 phase from 25% to a normal 4% and for the return of the G0/G1 phase to a 
normal 60% was faster for the H69CIS200 cells than the H69 cells. There was also an 
increase in the proportion of H69 cells in the G2/M phase, there was no such change for 
the H69CIS200 subline. The H69OX400 subline treated with 2000ng/ml oxaliplatin for 
2h showed little change in the cell cycle relative to those changes seen in the H69 cells. 
Even though 1000ng/ml cisplatin and 2000ng/ml oxaliplatin produced a more dramatic 
change in cell cycle in the H69 cells than in both the resistant sublines, when the 
H69CIS200 subline was acutely treated with double the dose (2000ng/ml cisplatin for 2h) 
and the H69OX400 subline with 4 times the dose (8000ng/ml oxaliplatin for 2h), the cell 
cycle profiles of the sublines resembled those for the H69 cells (not shown). The cell 
cycle kinetics were also determined during the development of the sublines following 
treatment cycle 4 and found to be the same as for the treated H69 cells (not shown). 
 
Cross resistance 
The H69CIS200 and H69OX400 cell sublines were equally resistant to cisplatin and 
oxaliplatin but they were not significantly resistant to carboplatin (Figure 6). Neither 
subline showed resistance to daunorubicin, epirubicin, etoposide, selenium or copper. 
However both the resistant sublines showed increased sensitivity to paclitaxel and 
taxotere. This increase in sensitivity was not associated with other mitotic spindle poisons 
such as vinblastine or navelbine. Rather the H69OX400 subline was resistant to 
vinblastine. The H69CIS200 subline was resistant to buthionine sulphoximine (BSO) 
while the H69OX400 subline was sensitive to BSO.  
 
Cellular glutathione and resistance 
To further investigate this differential effect of BSO, the levels of cellular glutathione 
was determined following 24h culture in fresh media. There was no significant difference 
in glutathione levels between the sublines and platinum drug treatment had no effect on 
glutathione levels (not shown). 50µM BSO depleted glutathione in all the cell lines to a 
similar extent of approximately 2% of the untreated level (not shown). 
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The effect of depleting cellular glutathione on cell growth and on resistance was 
determined by culturing the H69 cells and the resistant sublines in media containing 
50µM BSO. Figure 7a shows that BSO treatment reduced the growth of the H69 cells to 
65% of untreated cells, for the H69CIS200 subline the reduction was similar but for the 
H69OX400 subline growth was further inhibited. BSO tended to sensitise all cells to 
oxaliplatin, but had little effect on cisplatin resistance (Figure 7b,c). 
 
Platinum Accumulation 
There were no significant changes in the level of cell-associated platinum in the 
H69CIS200 or H69OX400 sublines relative to the H69 cells following a 2h exposure to 
1000ng/ml cisplatin, 2000ng/ml oxaliplatin or a 4-day exposure to 200ng/ml cisplatin or 
400ng/ml oxaliplatin (not shown). This suggests that changes in drug efflux or drug 
uptake were not contributing to resistance. 
 
Discussion 
 
Studies of cellular drug resistance mainly focus on the molecular mechanisms 
contributing to the resistance rather than how the cells became resistant and the factors 
that promote its development. In this study the H69 SCLC cells were treated either for 4 
days or 2h with an IC20 dose of cisplatin or oxaliplatin to determine the impact of 
cisplatin versus oxaliplatin and the length of drug exposure on the development of 
resistance. The time taken to develop stable resistance was approximately 8 months and 
this compares with the range of 4 months to 24 months reported for other cisplatin 
resistant SCLC sublines [26-33]. The rate of development of resistance appeared similar 
between the 2h and 4 day treatment schedules. However, the 4 day schedule produced 
stable resistance while the 2h schedule produced unstable resistance suggesting that a 
shorter pulse may be more effective against cancer than continuous exposure or longer 
pulse times.  This is similar to what was observed in the development of a cisplatin 
resistant ovarian carcinoma, which yielded stable resistance from a continuous exposure 
but not from a series of 1h pulses [34].  However other studies have produced stable 
cisplatin resistance with 1-2h pulses in murine ovarian reticulosarcoma [35], human 
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ovarian adenocarcinoma [36] and non-SCLC [37] using higher doses of drug (µmolar) 
than used in this study. 
 
Our results show that SCLC cells develop resistance to oxaliplatin more easily than they 
develop resistance to cisplatin. While we could find no other reports of oxaliplatin 
selected SCLC cells, there are many reports for other types of cell lines. Commonly 
reported mechanisms of resistance include increased cellular glutathione [38] and 
decreased platinum accumulation [39-41] similar to what is seen in cisplatin resistance. 
The H69CIS200 and H69OX400 sublines appear not to have decreased platinum 
accumulation nor increased glutathione but rather may rely on altered cell cycle kinetics 
as a means of resistance (Figs 4, 5). 
 
During the first five treatment cycles there was no measurable drug resistance yet the 
treated cells survived and regrew. Survival of these early treatment cycles involved a 
reversible cell cycle arrest followed by regrowth. Regrowth resistance has previously 
been reported as a mechanism that allows cells to survive drug treatment via proliferation 
rather than increased drug resistance [42]. Depending on the rate of proliferation and the 
sensitivity of the malignancy to therapy, the effects of tumor regrowth can range from 
insignificant to the complete offsetting of the effects of treatment [43]. After six 
treatment cycles the response of the resistant cells changed.  This is comparable to the 
resistance observed after 6 treatment cycles in cisplatin resistant SCLC [28] and 6 
treatment cycles in oxaliplatin resistant ovarian carcinoma [39].  
 
There was a shorter time to doubling for 3 out of the 4 resistant sublines and this change 
in response was accompanied by a change in the cell cycle kinetics following drug 
treatment (Fig 5). Earlier in the development of resistance (treatment cycle 4) treated 
cells showed a similar cell cycle recovery as the H69 cells.  A similar pattern of growth 
arrest and recovery was observed in the development of cisplatin resistant IGROV1 
ovarian carcinoma cells [36].  IGROV1 cells were exposed to cisplatin for 2h and 
allowed to recover for several weeks. Development of resistance to cisplatin was 
associated with the ability of the treated cells to progress through the cell cycle beyond 
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the G1/S checkpoint; although most cells died by apoptosis, a few surviving cells 
proliferated and recolonised the cultures. The authors suggested that this was not 
resistance to drug induced cell death, rather an increased propensity to proliferate after 
cytotoxic treatment [36], in other words regrowth resistance. It is likely that regrowth 
resistance is initially used as a survival mechanism that also provides the time for a more 
permanent protective mechanism to develop. 
 
Regrowth resistance is difficult to measure using a conventional 5 day cytotoxicity assay. 
The main reason for this is that regrowth does not occur within the time of the assay. 
Also the cytotoxicity assay depends on their being a change in growth rate or survival 
with changing dose of test drug. For regrowth resistance, growth arrest can occur over a 
wide drug concentration range effectively producing no change in growth or survival for 
the cytotoxicity assay to detect. Our sublines which survived dose escalation showed no 
increase in resistance in a conventional 5 day assay, however their survival is indicative 
of regrowth resistance. 
 
As to whether oxaliplatin is more effective than cisplatin, there is little in the way of 
direct comparisons in cellular resistance studies. Our results show resistance developed in 
a similar manner in response to cisplatin and oxaliplatin in our SCLC cell model. Both 
produced similar levels of resistance (Fig 3), drug cross-resistance (Fig 6) and stability of 
the resistance (Fig 3). However, it was easier to escalate the dose of oxaliplatin compared 
to cisplatin. A two-fold higher dose of cisplatin was cytotoxic to low-level resistant cells 
while a two-fold higher dose of oxaliplatin still resulted in viable cells. This suggests 
oxaliplatin may be less effective than cisplatin. This is also supported by the quicker 
recovery of growth from a single drug treatment for the H69OX400 subline compared to 
the H69CIS200 subline (Fig 4). A possible explanation for the faster recovery from 
oxaliplatin treatment and the greater number of oxaliplatin surviving sublines, is the 
greater efficiency of bypassing of oxaliplatin-DNA adducts than cisplatin-DNA adducts 
by DNA polymerases [44]. There is also further evidence to suggest that at equimolar 
concentrations oxaliplatin forms fewer but more cytotoxic DNA lesions than cisplatin 
[45,46]. This may explain the response of our sublines to equally cytotoxic doses of drug, 
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in the case of oxaliplatin there may be fewer lesions with a better chance of being 
bypassed by DNA polymerases. This combination leads to a greater chance of the 
oxaliplatin treated cell dividing, despite the presence of DNA lesions. The cell division 
will dilute out the number of lesions per cell and these surviving cells are likely to have 
additional attributes contributing to their mechanism of resistance to the platinum drug. 
 
There is evidence to suggest that oxaliplatin is active against cisplatin-resistant cancers 
and cells [8,9,12-14]. This has also been reported in SCLC, in one study the 16-fold 
cisplatin-resistant SR2 SCLC subline was sensitive to oxaliplatin [33] while another 
variant of this subline that was 3.3-fold resistant to cisplatin, was 1.4-fold resistant to 
oxaliplatin [47]. In our study of the H69 SCLC cells, oxaliplatin did not have activity 
against the cisplatin-resistant H69CIS200 cells and there are similar reports in ovarian 
carcinoma [40]. This also complements the clinical studies showing a lack of activity of 
oxaliplatin in cisplatin resistant ovarian carcinoma [17-19].  Our study questions the 
effectiveness of oxaliplatin in cisplatin resistant cancer and suggests that more research 
into the mechanisms of low-level platinum resistance is needed to resolve this issue. 
 
Even though oxaliplatin had little activity against cisplatin resistance in our study, 
paclitaxel and taxotere showed increased activity against both the H69CIS200 and 
H69OX400 sublines relative to the H69 cells (Fig 6). There are previous reports of 
cisplatin resistant SCLC cells being sensitised by pretreatment with a low dose of 
paclitaxel [28] and there are many examples of other cisplatin resistant cell lines that are 
sensitive to taxanes [48-52]. Taxanes bind to and stabilise microtubules and block cell 
cycle progression through centrosomal impairment, induction of abnormal spindles and 
suppression of spindle microtubule dynamics [53]. The mechanism of platinum resistance 
in these resistant sublines may involve tubulin abnormalities which then render the cells 
sensitive to subsequent paclitaxel treatment. This is supported by the report of cisplatin 
resistance being associated with decreased levels of β-tubulin and tubulin abnormalities 
[48,54]. Another possible explanation could involve survivin since this is increased in 
cisplatin resistant ovarian cancer cells and paclitaxel treatment reduces survivin levels in 
these cells [55]. 
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Increases in intracellular glutathione has been previously associated with platinum 
resistance in many studies [10,38,56].  We have determined that the level of glutathione 
remains unchanged between the cell lines and treatment with 50µM BSO tended to 
sensitise all cells to oxaliplatin, but had little effect on cisplatin resistance (Figure 7 b&c). 
This suggests that a depletion of glutathione is not enough to overcome the platinum 
resistance in this model. All the cell lines show a drop in growth rate in response to 50µM 
BSO (Figure 7a), however the H69OX400 cells show the most inhibition and the 
H69CIS200 cells grow more than the parental cells under these conditions. This 
corresponds to what was found in the BSO toxicity assay, the H69CIS200 cells are 
resistant and the H69OX400 cells are sensitive to BSO (Figure 6).  How this difference in 
response to BSO treatment relates to platinum resistance will be examined further in this 
cell model. 
 
We have shown that cisplatin and oxaliplatin treatment both cause the development of 
resistance in the H69 SCLC cell line in similar ways that initially involves growth arrest-
regrowth resistance followed by more permanent resistance mechanisms that appear not 
to involve decreased platinum accumulation or increased glutathione levels. Oxaliplatin 
was not effective against this cisplatin resistance however both resistant sublines were 
more sensitive to paclitaxel and taxotere suggesting the taxanes should be further 
investigated for their potential against platinum-resistant SCLC. 
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Table 1. Examples of cisplatin-selected SCLC sublines 
Subline 
(Fold Resistance) 
Treatment Ref. 
H69/0.2 (8) 
 
H69/0.4 (25) 
 
N231/0.2 (8) 
 
Continuous 50ng/ml for 1-3 weeks. Escalate dose to 
200ng/ml. 
Same as for H69/0.2 then grown in 400ng/ml for 1 
year. 
Continuous 50ng/ml for 1-3 weeks. Escalate dose to 
200ng/ml. 
[26] 
H69/CPR (5) 
 
Continuous exposure in escalating doses up to 
400ng/ml over 4-6 months. 
[27] 
H69-CP (3) 
 
H82-CP (2) 
 
6 treatments of 100ng/ml for 4 days with 2-3 weeks 
recovery between. 
6 treatments of 100ng/ml for 4 days with 2-3 weeks 
recovery between. 
[28] 
GLC4-CDDP (6) 
 
Continuous exposure with more drug added each time 
the cells grew. 9 such treatments over 1 year. 
Maintained by 1h exposure per month. 
[29] 
SBC-3/CDDP (13) 
 
Continuous starting at 30ng/ml for 2-3 weeks then 
escalating up to 1,500ng/ml over 2 years.  
[30] 
H209/CP (11.5) 
 
Continuous 80ng/ml for several months then 
maintained by treating every 2 weeks. 
[31] 
SW2/CDDP (3.3) 
 
IC90 dose for 1h per week with dose escalation of 15-
20% per treatment when possible over 14 months. 
[32] 
(SCLC1)SR-2 (16) 5ng/ml for 24h per 3 weeks; maintained with 100ng/ml [33] 
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Figure 1. Drug treatment regimens and the development of resistance. The H69 
SCLC cell line was treated with 12 different regiments as indicated. Cultures 
surviving a treatment are represented by a cell image while unsuccessful 
treatments are represented by a cross. 
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Figure 2. The recovery time following each treatment. The number of cells 
that exclude trypan blue were counted twice a week following treatment and 
the time taken to double cell number was determined.
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Figure 3. Resistance to cisplatin and oxaliplatin following each treatment. The 
resistance to cisplatin and to oxaliplatin was determined for 3 consecutive weeks 
following recovery from each treatment using a 5 day cytotoxicity assay in which 
viability was determined by the MTT assay. After 8 treatments the resistance was 
monitored weekly for 5 weeks.
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Figure 4. Effect of acute drug treatment on cell growth. The H69CIS200 and H69 
cells were treated with 1000ng/ml cisplatin for 2h and the H69OX400 and H69 cells 
were treated with 2000ng/ml oxaliplatin for 2h. The number of cells that exclude 
trypan blue were counted and the fold change was plotted vs time after treatment. 
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Figure 5. Effect of acute drug treatment on cell cycle. Cells were treated as described in 
Fig 4 and the proportion of cells in each phase of the cell cycle was determined by the 
propidium iodide/flow cytometry method described in Methods.
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Figure 6. Cross resistance of the H69 sublines. The cross resistance of  the 
H69CIS200 and H69OX400 sublines to the indicated drugs was determined 
using a 5 day cytotoxicity assay. The mean fold resistance relative to the H69 
cells is plotted. 
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Figure 7. Effect of glutathione depletion on cell growth and drug resistance. A) 
The number of cells which exclude trypan blue was determined after 3 days in 
culture +/- 50µM BSO. The IC50 for B) cisplatin and C) oxaliplatin was 
determined for a 5 day cytotoxicity assay in the presence and absence of 50µM 
BSO and the fold resistance calculated relative to the H69 cells in the absence of 
BSO. The means and standard deviations of  2 separate experiments is shown.
